Cargando…
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
PURPOSE: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933844/ https://www.ncbi.nlm.nih.gov/pubmed/33463593 http://dx.doi.org/10.4103/ijo.IJO_459_20 |